New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 3, 2014
05:47 EDTMCP, PFEStocks with implied volatility movement; PFE MCP
Stocks with implied volatility movement; Pfizer (PFE) 16, Molycorp (MCP) 91 according to iVolatility.
News For PFE;MCP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
March 23, 2015
09:37 EDTPFE, MCPActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL AUY SLB PFE MCP CELG VRTX SHPG GILD LOGI TSLA TASR NFLX SCTY WFM
08:55 EDTMCPChina rare earth exports down 2.7% from prior month in February, Bloomberg says
China's customs agency reported February rare earth exports of 4.36K tons vs. 4.48K tons in January, according to Bloomberg, citing an emailed statement from the agency. Rare earth miners include Molycorp (MCP), whose shares are up 28% to 46c in pre-market trading, and Rare Element Resources (REE).
08:06 EDTPFEPfizer, Eli Lilly to resume Phase 3 chronic pain program for Tanezumab
Pfizer (PFE) and Eli Lilly and Company (LLY) announced that they are preparing to resume the Phase 3 clinical program for tanezumab. As a result, Pfizer expects to receive a $200M upfront payment from Lilly in accordance with their collaboration agreement. This announcement follows a decision by the U.S. FDA to lift the partial clinical hold on the tanezumab development program after a review of a robust body of nonclinical data characterizing the sympathetic nervous system response to tanezumab. The data were submitted to the FDA in February. In the prior clinical studies of more than 11,000 patients, tanezumab demonstrated clinically meaningful efficacy vs. placebo and other select commonly used pain medicines. A partial clinical hold has been in place for tanezumab and all other anti-nerve growth factor antibodies since December 2012 due to adverse changes in the sympathetic nervous system of mature animals. Studies in terminal cancer pain were allowed to proceed.
08:05 EDTPFEPfizer, Eli Lilly to resume Phase 3 chronic pain program for Tanezumab
Subscribe for More Information
07:36 EDTPFEPfizer should rise 'significantly' over next two years, says Jefferies
Jefferies analyst Jeffrey Holford told investors this morning that he expects shares of Pfizer (PFE) to appreciate "significantly" over the next two years. A survey of U.S. oncologists indicated the company's Ibrance drug will be used in 50% of first line hormonal therapy within one year, with off-label use in all lines of therapy including adjuvant, Holford noted. He thinks peak sales of the drug could top $13B, which is well above consensus. In addition, the analyst views Pfizer's Global Established Pharmaceutical business as being underappreciated by the market. Potential value creating options for the pharmaceutical giant include spinning off its GEP unit by 2017 and accretive acquisitions, with possible takeover targets being Shire (SHPG), Actavis (ACT), AstraZeneca (AZN) and GlaxoSmithKline (GSK), in the eyes of Holford. He added the stock to the firm's Franchise Picks list, which encompasses its best ideas. He also raised his price target for Pfizer to $45 from $42. The stock closed Friday up 10c to $34.25.
March 20, 2015
13:03 EDTPFEPfizer says oral tofacitinib meets primary endpoint in Phase 3 trials
Subscribe for More Information
07:55 EDTPFEAstraZeneca seen as potential target again if oncology drugs lag, Bloomberg says
Subscribe for More Information
07:41 EDTPFEAmerican Academy of Dermatology to hold annual meeting
Subscribe for More Information
March 19, 2015
11:00 EDTPFEPfizer participates in a conference call with Bernstein
Subscribe for More Information
07:55 EDTMCPMolycorp bondholders led by Apollo close to hiring Blackstone, Bloomberg says
Subscribe for More Information
March 18, 2015
17:09 EDTPFEPfizer CAPiTA published in New England Journal of Medicine
Subscribe for More Information
15:22 EDTMCPMolycorp creditors close to hiring Blackstone, Bloomberg says
Subscribe for More Information
05:45 EDTMCPStocks with implied volatility movement; MCP FXCM
Stocks with implied volatility movement; Molycorp (MCP) 270, FXCM (FXCM) 86 according to iVolatility.
March 17, 2015
09:25 EDTMCPOn The Fly: Pre-market Movers
Subscribe for More Information
07:49 EDTMCPJPMorgan 'very concerned' about Molycorp capital levels
Subscribe for More Information
March 16, 2015
19:00 EDTMCPOn The Fly: After Hours Movers
Subscribe for More Information
17:31 EDTMCPMolycorp reports Q4 EPS (39c), consensus (26c)
Subscribe for More Information
15:25 EDTMCPNotable companies reporting after market close
Subscribe for More Information
07:44 EDTMCPmagicJack volatility elevated into Q4 and outlook
magicJack March call option implied volatility is at 83, April is a 124, April is at 71, June is at 61, September is at 50; compared to its 26-week average of 58 according to Track Data, suggesting large near term price movement into the expected release of Q4 results today after the market close.
06:40 EDTPFEPCSK9 studies show potential improvement in heart health, WSJ says
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use